Page 198 - 2019_04-Haematologica-web

P. Durigutto et al. References
1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for defi- nite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
2. Gerosa M, Meroni PL, Erkan D. Recognition and management of antiphospholipid syn- drome. Curr Opin Rheumatol. 2016;28(1): 51-59.
3. Chighizola CB, Andreoli L, de Jesus GR, et al. The association between antiphospho- lipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the litera- ture. Lupus. 2015;24(9):980-984.
4. Rodriguez-Pinto I, Moitinho M, Santacreu I, et al. Catastrophic antiphospholipid syn- drome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016;15(12): 1120-1124.
5. Pengo V, Bison E, Denas G, Jose SP, Zoppellaro G, Banzato A. Laboratory Diagnostics of Antiphospholipid Syndrome. Semin Thromb Hemost. 2018; 44(5):439-444.
6. Andreoli L, Nalli C, Motta M, et al. Anti- beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases prefer- entially target domain 4/5: might it be the reason for their 'innocent' profile? Ann Rheum Dis. 2011;70(2):380-383.
7. Andreoli L, Chighizola CB, Nalli C, et al. Clinical characterization of antiphospho- lipid syndrome by detection of IgG antibod- ies against beta2 -glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol. 2015; 67(8):2196-2204.
8. Bertolaccini ML, Sanna G. The Clinical Relevance of Noncriteria Antiphospholipid Antibodies. Semin Thromb Hemost. 2018; 44(5):453-457.
9. Chighizola CB, Pregnolato F, Andreoli L, et al. Beyond thrombosis: Anti-beta2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. J Autoimmun. 2018;90:76-83.
10. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330-339.
11. de Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol. 2008;4(4):192-199.
12. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998;95(26):15542-15546.
13. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epi- tope Gly40-Arg43 in domain I of beta 2-gly- coprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105(4):1540-1545.
14. Pengo V, Ruffatti A, Tonello M, et al. Antibodies to Domain 4/5 (Dm4/5) of beta2-Glycoprotein 1 (beta2GP1) in differ-
ent antiphospholipid (aPL) antibody profiles.
Thromb Res. 2015;136(1):161-163.
15. de Groot PG, Urbanus RT. The significance of autoantibodies against beta2-glycopro-
tein I. Blood. 2012;120(2):266-274.
16. Ioannou Y, Zhang JY, Passam FH, et al. Naturally occurring free thiols within beta 2- glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regu- lation of oxidative stress-induced cell injury.
Blood. 2010;116(11):1961-1970.
17. Passam FH, Rahgozar S, Qi M, et al. Beta 2
glycoprotein I is a substrate of thiol oxidore-
ductases. Blood. 2010;116(11):1995-1997. 18. Ioannou Y. The Michael Mason Prize: Pathogenic antiphospholipid antibodies, stressed out antigens and the deployment of decoys. Rheumatology (Oxford). 2012;
51(1):32-36.
19. de Laat B, Derksen RH, van Lummel M,
Pennings MT, de Groot PG. Pathogenic anti- beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006; 107(5):1916-1924.
20. de Laat B, Pengo V, Pabinger I, et al. The asso- ciation between circulating antibodies against domain I of beta2-glycoprotein I and throm- bosis: an international multicenter study. J Thromb Haemost. 2009; 7(11):1767-1773.
21. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candi- date biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev. 2012;12(2):313-317.
22. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost. 2015;13(5):782-787.
23. Chaturvedi S, McCrae KR. Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers. Curr Rheumatol Rep. 2017;19(7):43.
24. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinu- ous epitopes on domain I of human beta(2)- glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 2007;56(1):280-290.
25. Roggenbuck D, Borghi MO, Somma V, et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther. 2016;18(1):111.
26. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106(7):2340-2346.
27. Agostinis C, Durigutto P, Sblattero D, et al. A non-complement-fixing antibody to beta2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014; 123(22):3478-3487.
28. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis. 2007;66(10):1327-1333.
29. Pengo V. ISTH guidelines on lupus anticoag- ulant testing. Thromb Res. 2012;130 Suppl
1:S76-77.
30. Agostinis C, Biffi S, Garrovo C, et al. In vivo
distribution of beta2 glycoprotein I under various pathophysiologic conditions. Blood. 2011;118(15):4231-4238.
31. van Os GM, Meijers JC, Agar C, et al. Induction of anti-beta2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost. 2011;9(12):2447-2456.
32. Tomaic V, Gardiol D, Massimi P, Ozbun M, Myers M, Banks L. Human and primate tumour viruses use PDZ binding as an evo- lutionarily conserved mechanism of target- ing cell polarity regulators. Oncogene. 2009;28(1):1-8.
33. Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ. Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem J. 1991; 277( Pt 2):387-391.
34. Agar C, van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 confor- mations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116(8):1336-1343.
35. de Groot PG, Meijers JC. beta(2) - Glycoprotein I: evolution, structure and function. J Thromb Haemost. 2011; 9(7):1275-1284.
36. Pengo V, Testa S, Martinelli I, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res. 2015;135(1):46-49.
37. Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost. 2009;7(5):833-842.
38. Agnello V, Koffler D, Kunkel HG. Immune complex systems in the nephritis of sys- temic lupus erythematosus. Kidney Int. 1973;3(2):90-99.
39. McPhaul JJ Jr, Mullins JD. Glomerulonephritis mediated by antibody to glomerular basement membrane. Immunological, clinical, and histopathologi- cal characteristics. J Clin Invest. 1976; 57(2):351-361.
40. Salmon JE, Girardi G. Theodore E. Woodward Award: antiphospholipid syn- drome revisited: a disorder initiated by inflammation. Trans Am Clin Climatol Assoc. 2007;118:99-114.
41. Erkan D, Salmon JE. The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome. Turk J Haematol. 2016;33(1):1-7.
42. Oku K, Nakamura H, Kono M, et al. Complement and thrombosis in the antiphospholipid syndrome. Autoimmun Rev. 2016;15(10):1001-1004.
43. Meroni PL, Macor P, Durigutto P, et al. Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood. 2016;127(3):365-367.
44. Del Papa N, Sheng YH, Raschi E, et al. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phos- pholipid binding and offers epitopes for anti- beta 2-glycoprotein I antibodies. J Immunol. 1998;160(11):5572-5578.
826
haematologica | 2019; 104(4)